Home › Janssen Stands United with Patients on World IBD Day 2018
Janssen Stands United with Patients on World IBD Day 2018
Janssen Stands United with Patients on World IBD Day 2018
On May 19, we recognize World Inflammatory Bowel Disease (IBD) Day at Janssen by shedding light on the more than five million people around the world affected by Crohn’s disease and ulcerative colitis (UC).
At Janssen, we are focused on learning more about the immune system to improve the lives of those living with debilitating immune diseases like IBD. Our scientists collaborate with researchers, healthcare providers, academic and patient organizations around the world to advance the science and develop innovative treatments to promote health and prevent, intercept and cure diseases. That’s why this year, Janssen and Johnson & Johnson Innovation, JLABS are seeking external innovators to submit their ideas for the IBD Stress Test QuickFire Challenge to evaluate immune and gastrointestinal health and ultimately predict risk of IBD. Submit your application today!
Additionally, in honor of World IBD Day, mark your calendar for the #TalkIBD Twitter Chat hosted by @JanssenEMEA and @TalkHealth on May 18 at 8:00 a.m. ET. You can also showcase your support on May 19 by posting on social media using #WorldIBDDay as we stand united with all of those impacted by IBD.
Scott Plevy, M.D. is a distinguished, board-certified gastroenterologist who joined Janssen Immunology after a successful career in academia. He has been the lead investigator on multiple early-phase clinical trials and led translational research to advance the understanding of novel immunologic interventions. In addition, Scott has contributed to more than 80 peer-reviewed publications concentrating on inflammatory bowel disease (IBD). As IBD Disease Area Leader, Scott is responsible for outlining strategies to advance new paradigms for treatment and intervention, collaborating with several external groups to identify priority targets for drug discovery and development that will enhance the current IBD portfolio.
Albert Lee has spent more than 20 years at Johnson & Johnson, in roles of increasingly responsibility including sales, marketing and general management across different geographies and franchises. In recognition of his leadership and passionate involvement in the Healthcare industry, Albert was elected Chairman for Medical Technology Industry Group by Singapore Manufacturing Federation (SMF MTIG) since 2014. Albert is also on the Board of Directors of Singapore Association of Pharmaceuticals Industries (SAPI) and on the Alumni Advisory Board of Nanyang Technological University Business School. He is also a Member of Medical Devices Industry Policy Review Working Group, Health Sciences Authority (HSA).